Nilvadipine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nilvadipine
Nilvapidine.png
Systematic (IUPAC) name
5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
?
Identifiers
CAS number  YesY
ATC code C08CA10
PubChem CID 4494
DrugBank DB06712
ChemSpider 4338 N
UNII 0214FUT37J YesY
KEGG D01908 YesY
ChEMBL CHEMBL517427 N
Chemical data
Formula C19H19N3O6 
Molecular mass 385.370 g/mol
 N (what is this?)  (verify)

Nilvadipine is a calcium channel blocker (CCB) used for the treatment of hypertension and chronic major cerebral artery occlusion.

Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.

Nilvadipine was tested in clinical trial as a possible treatment for Alzheimer's Disease in Ireland by the Roskamp Institute, Florida, USA and Trinity College, Ireland.[1]

Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of Nilvadipine.[2]

References[edit]